Rigel Pharmaceuticals (RIGL) Amortization of Deferred Charges (2021 - 2022)

Rigel Pharmaceuticals' (RIGL) quarterly Amortization of Deferred Charges came in at $682000.0 in Q1 2022, up 1036.67% year-on-year from $60000.0 in Q1 2021, and down 17.33% quarter-over-quarter from $825000.0 in Q4 2021.

Rigel Pharmaceuticals (RIGL) Amortization of Deferred Charges (2021 - 2022) Analysis & Trends

Rigel Pharmaceuticals' Amortization of Deferred Charges history runs 2 years deep, the most recent figure standing at $682000.0 for Q1 2022.

  • On a quarterly basis, Amortization of Deferred Charges rose 1036.67% year-over-year to $682000.0 in Q1 2022; TTM through Dec 2022 was $682000.0, a 78.27% decrease from a year earlier, with the FY2022 full-year figure at $682000.0, down 78.27% from the prior year.
  • Amortization of Deferred Charges retreated to $682000.0 in Q1 2022 per RIGL's latest filing, from $825000.0 in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q2 2021 and bottomed at $60000.0 in Q1 2021.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn
4 NuCana 279.75 Bn 279.75 Bn -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn
7 Belite Bio 62.51 Bn 62.51 Bn -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn
9 Revolution Medicines 37.78 Bn 37.78 Bn -
10 Rigel Pharmaceuticals 681.25 Mn 534.56 Mn 54.21 Mn

Historic Data

Download Data
DateValue
Mar 31, 2022 682,000.00
Mar 31, 2022 682,000.00
Dec 31, 2021 825,000.00
Dec 31, 2021 825,000.00
Sep 30, 2021 886,000.00
Sep 30, 2021 886,000.00
Jun 30, 2021 1.37 Mn
Jun 30, 2021 1.37 Mn
Mar 31, 2021 60,000.00
Mar 31, 2021 60,000.00